Teva launches generic versions of 2 antibiotics in US

Teva

Pfizer's Zyvox and USP's Nafcillin have annual sales of over $500 million in the US.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has launched generic versions of two antibiotics in the US.

These include the first generic equivalent to Zyvox (linezolid), an injectable antibiotic for the treatment of severe infections, and Nafcillin for injection, which is from the same family as penicillin for the treatment of infections.

Zyvox, marketed by Pfizer, had annual sales of about $464 million in the US, according to IMS data as of October 2014. Nafcillin, marketed by USP, had annual sales of about $55 million in the US, according to IMS data as of September 2014.

Published by Globes [online], Israel business news - www.globes-online.com - on January 6, 2015

© Copyright of Globes Publisher Itonut (1983) Ltd. 2015

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018